Biologic therapies in primary Sjögren's syndrome.

SJ Bowman - Current Pharmaceutical Biotechnology, 2012 - europepmc.org
Primary Sjögren's Syndrome (PSS) is characterized by dryness of the eyes and mouth due
to lymphocytic infiltration of secretory exocrine glands. As well as disabling dryness, patients …

Biologic treatments in Sjögren's syndrome

S Bowman, F Barone - La Presse Médicale, 2012 - Elsevier
Primary Sjögren's Syndrome (pSS) is characterized by focal lymphocytic infiltration of
secretory exocrine glands associated with severe dryness of eyes and mouth in particular …

Rituximab in primary Sjögren's syndrome: a ten-year journey

F Carubbi, A Alunno, P Cipriani, E Bartoloni… - Lupus, 2014 - journals.sagepub.com
Primary Sjögren's syndrome (pSS) is an autoimmune disorder affecting exocrine glands and
characterized in most cases by a rather mild clinical picture. However, a subgroup of pSS …

Use of Rituximab in the Management of Sjögren's Syndrome

F Carubbi, A Alunno, P Cipriani, O Berardicurti… - … Treatment Options in …, 2015 - Springer
Opinion statement Primary Sjögren's syndrome (pSS) is an autoimmune disease, showing a
broad heterogeneity concerning the symptoms, the involved organs, as well as the …

Indications and options of new immune modulatory therapies for Sjögren's syndrome

E Feist, T Dörner, A Hansen - Zeitschrift fur Rheumatologie, 2007 - europepmc.org
Sjögren's syndrome is a systemic inflammatory rheumatic disorder of unknown origin with so
far inadequate therapy options. Management of Sjögren's syndrome is still primarily …

Present and novel biologic drugs in primary Sjögren's syndrome

S Fasano, DA Isenberg - Clinical and experimental …, 2019 - discovery.ucl.ac.uk
Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease characterised by
xerostomia and xerophthalmia. In at least one-third of patients, the disease may be …

Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double‐blind, placebo‐controlled trial

JM Meijer, PM Meiners, A Vissink… - Arthritis & …, 2010 - Wiley Online Library
Objective. To study the efficacy and safety of B cell depletion with rituximab, a chimeric
murine/human anti-CD20 monoclonal antibody, in patients with primary Sjögren's syndrome …

Efficacy of rituximab in systemic manifestations of primary Sjögren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry

JE Gottenberg, G Cinquetti, C Larroche… - Annals of the …, 2013 - ard.bmj.com
Objectives To evaluate the efficacy and safety of rituximab in patients with primary Sjögren's
syndrome (pSS). Methods The AutoImmune and Rituximab registry has included 86 patients …

Rituximab therapy for primary Sjögren's syndrome

YH Chen, XY Wang, X Jin, Z Yang, J Xu - Frontiers in Pharmacology, 2021 - frontiersin.org
Primary Sjögren's syndrome (pSS) is a systemic autoimmune diseases of the connective
tissues, characteristic of the presentation of keratoconjunctivitis sicca and xerostomia. A …

The TRACTISS Protocol: a randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy In patients with primary Sjögren's Syndrome

S Brown, N Navarro Coy, C Pitzalis, P Emery… - BMC musculoskeletal …, 2014 - Springer
Abstract Background Primary Sjögren's Syndrome (PSS) mainly affects women (9: 1 female:
male ratio) and is one of the commonest autoimmune diseases with a prevalence of 0.1 …